Condition
Fibroblast
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Unknown1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06911476Not Yet Recruiting
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
NCT01154842UnknownPrimary
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
Showing all 2 trials